Article

Interscience Conference on Antimicrobial Agents and Chemotherapy--49th annual meeting. Part 1. 11-15 September 2009, San Francisco, CA, USA.

Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK.
IDrugs: the investigational drugs journal (impact factor: 2.28). 11/2009; 12(11):667-9.
Source: PubMed

ABSTRACT The Interscience Conference on Antimicrobial Agents and Chemotherapy held in San Francisco included topics covering new therapeutic developments for the treatment of infectious diseases. This conference report highlights selected presentations on a beta-cyclodextrin derivative for the treatment of Staphylococcus aureus infections, a type 3 secretion system inhibitor for the treatment of Pseudomonas aeruginosa infections, a small-molecule inhibitor of the fungal Hos2 HDAC, a TLR9 agonist used as an adjuvant, a CMV vaccine, a glycopeptide-cephalosporin heterodimer antibiotic, a topical quinolone for the treatment of complicated skin and skin structure infections, a broad-spectrum glycylcycline antibiotic and an HCV RNA replication inhibitor. Investigational drugs discussed include IB-201 (Innovative Biologics Inc), MBX-1641 (Microbiotix Inc), MGCD-290 (MethylGene Inc), agatolimod (Coley Pharmaceutical Group Inc/Pfizer Inc/GlaxoSmithKline plc/Merck & Co Inc/Dynavax Technologies Corp/Novartis AG/Emergent BioSolutions Inc), TD-1792 (Theravance Inc), ozenoxacin (Ferrer Internacional SA/Maruho Co Ltd/Toyama Chemical Co Ltd) and ATI-0810 (Arisyn Therapeutics Inc).

0 0
 · 
1 Bookmark
 · 
83 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

Antimicrobial Agents
 
Arisyn Therapeutics Inc
 
broad-spectrum glycylcycline antibiotic
 
Coley Pharmaceutical Group Inc/Pfizer Inc/GlaxoSmithKline plc/Merck & Co Inc/Dynavax Technologies Corp/Novartis AG/Emergent BioSolutions Inc
 
conference report
 
Ferrer Internacional SA/Maruho Co Ltd/Toyama Chemical Co Ltd
 
glycopeptide-cephalosporin heterodimer antibiotic
 
HCV RNA replication inhibitor
 
Innovative Biologics Inc
 
Interscience Conference
 
MethylGene Inc
 
Microbiotix Inc
 
ozenoxacin
 
skin structure infections
 
Staphylococcus aureus infections
 
Theravance Inc
 
TLR9 agonist
 
topics
 
type 3 secretion system inhibitor
 

Ben Turner